New trial aims to slash deadly bloodstream infections from hospital tubes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Core inclusion Criteria: * The patient has or requires a CVAD, including a PICC, a non-tunnelled or tunnelled CVC, or a totally implanted venous access port. * Patient is less than 18 years old and paediatric recruitment has not been approved at the site. Securement Domain exclusion criteria: * Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ. * CLABSI diagnosed from any vascular access device currently in situ within the past 7 days or being actively treated with antimicrobials. * Participants with an estimated life expectancy of \<30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway. * Participants who have previously been randomised for the same CVAD. * Participants who have been randomised three times. * SecurAcath® cannot be applied in accordance with manufacturer instructions and local policy. * The participant has compromised skin integrity at the current or intended insertion site, including active infection, inflammation, erosion, ulceration, or pre-existing exit-site injury. Connectors/Caps Domain exclusion criteria: * Central line-associated bloodstream infection (CLABSI) currently suspected associated with any vascular access device (peripheral or central) that is in situ. * CLABSI diagnosed within the past 14 days or CLABSI being actively treated with antimicrobials, associated with any vascular access device currently in situ. * Participants with an estimated life expectancy of \<30 days OR who have commenced a documented end-of-life, terminal-care, or comfort-care pathway. * Participants who have previously been randomised for the same CVAD. * Participants who have been randomised three times. * Known or suspected hypersensitivity or a confirmed allergy to chlorhexidine. Cancer stratum inclusion criteria: * Confirmed diagnosis of a solid tumour OR * Confirmed diagnosis of a haematological malignancy. OR * Bone marrow failure syndrome requiring systemic therapy, immunosuppression, or haematopoietic stem cell transplantation. Kidney stratum exclusion criteria: * Confirmed diagnosis of kidney failure treated with haemodialysis AND * CVAD expected to remain in place for \>14 days.